异基因造血干细胞移植后眼部移植物抗宿主病的发病率及危险因素
Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation.
作者信息
Na K-S, Yoo Y-S, Mok J W, Lee J W, Joo C-K
机构信息
Department of Ophthalmology and Visual Science, Yeouido St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Catholic Institutes of Visual Science, The Catholic University of Korea, Seoul, Korea.
出版信息
Bone Marrow Transplant. 2015 Nov;50(11):1459-64. doi: 10.1038/bmt.2015.187. Epub 2015 Aug 24.
We analyzed the incidence and risk factors for ocular GVHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Korea. In this retrospective, noncomparative, observational study, 635 subjects were included who had at least 2 years of follow-up ophthalmological examinations after allo-HSCT from 2009 to 2012 at Seoul St Mary's Hospital, Seoul, Korea. The mean duration between allo-HSCT and onset of ocular GVHD was 225.5±194.3 days. The adjusted incidence for acute ocular GVHD was 1.33% and that for chronic GVHD was 33.33%. In the multivariate analysis, preexisting diabetes mellitus (odds ratio (OR): 4.22, 95% confidence interval (CI): 1.66-10.72), repeated allo-HSCT (OR: 29.10, 95% CI: 1.02-8.28) and the number of organs that chronically developed GVHD by stage I (OR: 14.63, 95% CI: 9.81-21.84) increased risk of ocular GVHD. Careful monitoring of ocular GVHD is needed in patients with chronic GVHD in multiple organs and preexisting diabetes.
我们分析了韩国接受异基因造血干细胞移植（allo-HSCT）患者眼部移植物抗宿主病（GVHD）的发病率及危险因素。在这项回顾性、非对照、观察性研究中，纳入了635名在2009年至2012年期间于韩国首尔圣母医院接受allo-HSCT后至少有2年眼科随访检查的受试者。allo-HSCT至眼部GVHD发病的平均时长为225.5±194.3天。急性眼部GVHD的校正发病率为1.33%，慢性GVHD为33.33%。多因素分析显示，既往糖尿病（比值比（OR）：4.22，95%置信区间（CI）：1.66 - 10.72）、重复allo-HSCT（OR：29.10，95%CI：1.02 - 8.28）以及I期慢性发生GVHD的器官数量（OR：14.63，95%CI：9.81 - 21.84）会增加眼部GVHD的风险。对于多器官慢性GVHD和既往糖尿病患者，需要密切监测眼部GVHD。
Zotero 插件